Continuous Renal Replacement Therapy (CRRT) Market Size, Share | 2032

Report Description

Market Outlook:

The Global Continuous Renal Replacement Therapy (CRRT) market was estimated at USD 1,460.4 Million in 2023 and is anticipated to reach USD 2,966.7 Million by 2032, expanding at a CAGR of 8.4% during the forecast period.

Continuous Renal Replacement Therapy (CRRT) is a form of dialysis used to treat critically ill patients with acute kidney injury or other forms of kidney failure. Unlike traditional intermittent forms of dialysis, CRRT provides continuous removal of waste products and excess fluid from the blood over a longer period of time, typically 24 hours a day. This slower and more gentle method of dialysis is often preferred for hemodynamically unstable patients in the intensive care unit, as it allows for more stable control of fluid and electrolyte balance.

Get Free Sample Report

COVID-19 Impact on the Global Continuous Renal Replacement Therapy (CRRT) Market

The global continuous renal replacement therapy (CRRT) market has been significantly impacted by the COVID-19 pandemic, with the increased prevalence of acute kidney injury in critically ill COVID-19 patients driving up the demand for CRRT services. This surge in demand has put pressure on healthcare facilities to provide adequate CRRT equipment and supplies, leading to challenges in the supply chain. For instance, some regions have experienced shortages of CRRT machines and consumables due to the increased demand during the pandemic. However, the crisis has also sparked innovation in the CRRT market, with the development of new technologies and telemedicine solutions to remotely monitor and manage CRRT treatments for COVID-19 patients. These advancements have not only improved patient care but also reduced the risk of exposure to the virus for healthcare providers. Overall, the ongoing pandemic continues to shape the CRRT market, with a mix of challenges and opportunities emerging as healthcare systems navigate the impact of COVID-19.

Another impact of the pandemic on the CVVH market has been the increased demand for renal replacement therapy in critically ill COVID-19 patients. The virus has been associated with a high prevalence of acute kidney injury, which has led to a higher number of patients requiring CRRT treatment. This surge in demand has strained healthcare systems and hospitals, leading to challenges in providing timely and adequate care to all patients in need of CRRT therapy.

For instance, In August 2020, the US Food and Drug Administration approved Baxter's Regiocit, a CRRT replacement product for emergency usage during the COVID-19 pandemic. However, while this medicine only has an emergency use authorization (EUA) in the US, it is approved and in use in a number of counties in Asia and Europe.

Artificial Intelligence (AI) Impact on the Global Continuous Renal Replacement Therapy (CRRT) Market

The integration of Artificial Intelligence (AI) in the healthcare industry has had a significant impact on the global Continuous Renal Replacement Therapy (CRRT) market. AI technologies have revolutionized the way CRRT is administered and managed, leading to improved efficiency, accuracy, and patient outcomes.

One major impact of AI on the CRRT market is in predictive analytics and personalized treatment approaches. AI algorithms can analyze large volumes of patient data to predict the likelihood of acute kidney injury and identify the most effective CRRT treatment options for individual patients. This personalized approach allows healthcare providers to optimize CRRT therapy and improve patient outcomes.

Furthermore, AI-powered systems can automate certain aspects of CRRT treatment, such as monitoring patients' vital signs, adjusting fluid removal rates, and detecting early signs of complications. This automation helps healthcare providers deliver more precise and timely care, reducing the risk of errors and improving treatment efficiency.

Additionally, AI enables remote monitoring and telehealth services for CRRT patients, allowing healthcare providers to track patients' progress, adjust treatment plans, and provide real-time support from a distance. This remote capability has become particularly valuable during the COVID-19 pandemic, enabling healthcare providers to deliver CRRT services to patients while minimizing the risk of exposure to the virus.

Macro-economic Factors

Healthcare Expenditure

The healthcare expenditure has a significant impact on the continuous renal replacement therapy (CRRT) market. The demand for cost-effective and efficient treatment options, such as CRRT, is increasing, as healthcare costs continue to rise. CRRT is a vital treatment for patients with acute kidney injury or chronic kidney disease who require long-term renal support.

The continuous nature of CRRT allows for improved management of fluid balance and electrolyte imbalances, which is particularly beneficial for critically ill patients. Additionally, CRRT is administered at the patient bedside, reducing the need for frequent transfers to a dialysis unit. This convenience and effectiveness contribute to the growing demand for CRRT in the healthcare industry.

The high cost of CRRT equipment, consumables, and the need for specialized staff are a barrier to its widespread adoption. Therefore, governments and insurance providers are increasingly recognizing the value of CRRT and are adjusting their reimbursement policies accordingly. This shift in policy helps make CRRT increasingly accessible to patients in need.

Healthcare expenditure plays a crucial role in shaping the CRRT market. The market for CRRT is expected to expand in the coming years, driven by advancements in technology and evolving healthcare policies, as the demand for efficient and effective treatment options continues to grow.

Market Dynamics

Major Driver- Increase in Number of Dialysis Centers Fueling Continuous Renal Replacement Therapy Market

The increase in the number of dialysis centers is expected to drive the global continuous renal replacement therapy market over the forecast period. The market growth is attributed to the increased prevalence of acute kidney injury (AKI), the presence of a significant number of hospitals in the US, and a well-developed healthcare infrastructure. For example, Fresenius Medical Care owned and managed around 3,928 dialysis clinics in 2018, compared to 3,752 in 2017. According to the American Hospital Association, the US has 5,141 community hospitals, 625 nonfederal psychiatric institutions, and 208 federal government hospitals in 2021.

According to the Centers for Disease Control and Prevention, about 786,000 people in the US were living with end-stage renal disease (ESRD) in 2021, with 71% on dialysis and 29% requiring kidney transplant. Thus, the rising prevalence of end-stage renal illness has resulted in an increase in the number of dialysis clinics and treatment facilities. Leading industry participants are launching initiatives to reach the majority of ESRD patients in all regions by expanding the number of dialysis centers. For example, B. Braun Melsungen AG alone operates over 300 locations in Europe, Africa, and Asia Pacific.

Existing Restraint- High Treatment Costs and Preference for Conventional Dialysis

The high treatment costs associated with continuous renal replacement therapy (CRRT) act as a significant barrier to the market demand. Both healthcare facilities and individuals find the costs associated with CRRT operations, equipment, and continuous maintenance prohibitively high. This financial burden makes CRRT less accessible, especially in places with tight budgets and healthcare systems suffering economic issues. Therefore, financial considerations cause healthcare professionals and organizations to choose cost-effective options, hindering the wide adoption of CRRT.

The preference for traditional dialysis procedures over CRRT serves as a significant constraint. Despite the benefits of CRRT, established procedures and familiarity with standard intermittent hemodialysis result in resistance to change among healthcare personnel and facilities. This preference for traditional procedures, which is influenced by previous practices and comfort levels, impedes widespread acceptance and incorporation of CRRT into normal renal care protocols, reducing the market demand and uptake.

Emerging Opportunity- Innovating Solutions to Deliver an Accurate and Rapid Diagnosis of Chronic Diseases

Innovative technologies for providing accurate and timely diagnosis of chronic diseases are critical for improving patient treatment and overall health outcomes. Advanced technology and methodologies are used to create efficient and effective diagnostic tools that meet the issues associated with chronic diseases.

The increasing prevalence of chronic diseases is a driver for emerging big data technologies for healthcare, including digital platforms for data collection, systems for active patient engagement & education, therapy specific predictive models, and optimized patient pathway models. Powerful bioelectronic medicine tools for data collection, analysis, and visualization allow for joint processing of large volumes of heterogeneous data. These produce new insights about patient outcomes and alternative interpretations of clinical patterns that lead to implementation of optimized clinical decisions and clinical patient pathway by healthcare professionals.

Key players are using collaboration, mergers, and acquisition strategies to get a competitive advantage in the industry and grow their operations. For example, in April 2020, Lucid Health partnered with Riverain Technologies to create AI-powered medical imaging and radiology products. Healthy.io purchased Inui Health in June 2020, and the company intends to use the acquisition to provide superior home healthcare urinalysis solutions.

Scope of the Report  

The report on the Global Continuous Renal Replacement Therapy (CRRT) market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
 

Segmental Outlook

On the basis of product type, the continuous renal replacement therapy (CRRT) market is categorized as consumables and systems. The consumables segment held 63.2% share of the market in 2023, owing to the growing demand for CRRT procedures globally, particularly in intensive care units (ICUs), which drives the demand for consumables such as dialysates, replacement solutions, filters, catheters, and others. This increased demand is attributed to the rising incidence of acute kidney injury (AKI) and acute kidney failure (AKF) among critically ill patients. For instance, according a recent article published in Springer Nature, globally, AKI affects more than 13 million individuals and causes 1.7 million deaths annually. This is expected to increase the demand for continuous renal replacement therapy consumables during the forecast period.

Get Free Sample Report

Based on modality, the continuous renal replacement therapy (CRRT) market is segmented into slow continuous ultrafiltration (SCUF), continuous venovenous hemofiltration (CVVH), continuous venovenous haemodialysis (CVVHD), and continuous venovenous hemodiafiltration (CVVHDF). The continuous venovenous hemofiltration (CVVH) segment is anticipated to hold 34.8% share of the market in 2032, owing to the expansion of CVVH applications. Additionally, CVVH is being explored for potential applications beyond AKI and CKD, such as management of severe sepsis and poisoning & intoxication. This is expected to increase the demand for continuous renal replacement therapy during the forecast period.

Get Free Sample Report

Regional Outlook

On the basis of region, the Global Continuous Renal Replacement Therapy (CRRT) market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa (MEA).

The market in North America is projected to expand at a CAGR of 8.6% during the forecast period, owing to the rising incidence of chronic kidney disease in North America. This, in turn, boosts the demand for continuous renal replacement therapy in the region. For instance, according to data by an annual report of United States Renal Data System 2020, end-stage kidney disease (ESKD), also known as end-stage renal disease (ESRD), affects almost 808,000 people in the US, with 69% on dialysis and 31% requiring a kidney transplant. Additionally, in 2022, a total of 25,499 kidney transplants were performed in the US. This is expected to increase the demand for continuous renal replacement therapy (CRRT) in the region.

Europe accounted for 26.12% share of the market in 2023. The market in Europe is projected to expand at a CAGR of 8.2% during the forecast period, due to the increasing prevalence of diabetes. For instance, the International Diabetes Federation projects that diabetes prevalence (9.2%) and the number of people with diabetes (61 million) in Europe is projected to increase by about 13% by 2045. This is anticipated to boost the demand for continuous renal replacement therapy in this region.

Get Free Sample Report

Key Benefits for Industry Participants & Stakeholders

• In-depth Analysis of the global Continuous Renal Replacement Therapy (CRRT) Market

• Historical, Current, and Projected Market Size in terms of Value

• Potential & Niche Segments and Regions Exhibiting Promising Growth Covered

• Industry Drivers, Restraints, and Opportunities Covered in the Study

• Recent Industry Trends and Developments

• Competitive Landscape & Strategies of Key Players

• Neutral Perspective on Global Continuous Renal Replacement Therapy (CRRT) Market performance